Business · 19/12/2011Updated: 10/17/2026 · 1 min read
FDA Issues Interim Final Rule on Postmarketing Reporting Requirements for Discontinuing Drug Products
Summary
The FDA is revising its postmarketing reporting regulations to improve the collection and distribution of drug shortage information, and to enhance collaboration with manufacturers and other stakeholders to address potential shortages.
Original source language: Federal Register — Health and Human ServicesOpen original release →